Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor
Doctors at the Mayo Clinic in MN seek patients with malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent) to trial a therapeutic vaccine. This vaccine contains a genetically engineered virus designed to target tumors. Other eligible tumors: Neurofibromatosis Type 1
The virus is a modified version of the measles virus used to vaccinate children. The virus has been altered by having an extra gene (piece of DNA) added to it that helps the body concentrate iodine. Having this additional gene will make it possible to track where the virus goes in the body, through a scan a few days after the injection of the drug to the tumor.
- Be 18 years of age and older
- Not be pregnant or breastfeeding
- Meet lab assessment requirements for overall health status
- Allergy to measles vaccine or history of severe reaction to prior measles vaccination
THE STUDY INVOLVES:
- Screening to confirm acceptance to the study.
- Intratumoral (into the tumor) injection of the vaccine.
- Undergo PET scans over the next 30 days and at 6 weeks.
- Follow up will continue for up to 2 years
LOCATIONS & CONTACTS:
The study will take place at Mayo Clinic in Rochester in Rochester, MN, Map.
Mayo Clinical Trials Referral Office | 855-776-0015
National Cancer Institute (NCI)
Or go online: